For patients with a condition called End Stage Renal Disease (ESRD), dialysis procedures allow them to clean their blood when their kidneys can no longer perform that job. As a part of dialysis, many treatment facilities used a chemical called Granuflo Dry Acid Concentrate, which is a component of the DIALYSATE, used during hemodialysis treatment. Granuflo causes increased levels of bicarbonate in the blood, which can lead to a heart attack and death. In June 2012, the FDA issued a Class I recall of Granuflo Dry Acid Concentrate. Both the manufacturers of Granuflo, Fresenius, and hemodialysis centers are now facing lawsuits regarding the use of the GranuFlo product, and as Healio reports, a jury has now awarded three victims a total of $383.5 million.
In June, a Denver, Colorado federal jury awarded a total of $383.5 million to the families of three patients who died after receiving hemodialysis treatments at clinics run by DaVita.
The attorneys for the plaintiffs successfully argued that the clinics used GranuFlo, a product known to cause pH balances that can lead to cardiac arrest and stroke. The lawsuits were filed against DaVita in 2013, just after the FDA issued a recall of GranuFlo.
The plaintiff’s attorneys argued that had the DaVita-run clinics inspected the GranuFlo and paid attention to blood tests, they would have noticed the elevated levels of bicarbonate, and should have stopped treatment.
Each of the families was awarded $125 million, with compensatory damages ranging from $1.5 million to $5 million.
DaVita announced that they intend to appeal the verdict.
Have you been injured? We can help. Call today.